The MarketVue®: ANCA-associated vasculitis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Previously a life-threatening disease, there has been improvement in prognosis for AAV since introduction of immunosuppressive treatments to manage the condition - non-steroidal immunosuppressants with corticosteroids is the current standard of care.
While corticosteroids effectively induce and sustain remission, findings from this MarketVue® assessment show that >60% of surveyed physicians report high need for steroid-sparing induction and maintenance treatments, due to concerns over safety associated with long-term steroid use. As one rheumatologist comments: 'To not require steroids would be very good, and that was the purpose of the avacopan trial.'
Physicians are eager for steroid-sparing treatments, which explains the positive feedback about avacopan’s ability to get patients off steroids in as quickly as a month.
An analyst from the research firm, stated: 'To supplant current therapies, newer agents must be able to induce long-term remission, reduce corticosteroid burden, and prevent relapses.'
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: ANCA-associated vasculitis report is supported by 5 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research. Qualitative interview participants included 3 Rheumatologists, 1 Nephrologist, and 1 Pulmonologist (all U.S.).Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).Key companies mentioned:
- Amgen
- GlaxoSmithKline
- ChemoCentryx / Amgen
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- AstraZeneca
Key drugs mentioned:
- Avacopan (Tavneos)
- Mepolizumab (Nucala)
- Rituximab
- Cyclophosphamide (Cytoxan)
- Azathioprine
- Mycophenolate mofetil
- Methotrexate
- Glucocorticoids
- Prednisone
- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- BDB-001
- Depemokimab
Key takeaways from the report:
AAV is a chronic organ-threatening autoimmune condition marked by inflammation of small-to-medium blood vessels.Previously a life-threatening disease, there has been improvement in prognosis for AAV since introduction of immunosuppressive treatments to manage the condition - non-steroidal immunosuppressants with corticosteroids is the current standard of care.
While corticosteroids effectively induce and sustain remission, findings from this MarketVue® assessment show that >60% of surveyed physicians report high need for steroid-sparing induction and maintenance treatments, due to concerns over safety associated with long-term steroid use. As one rheumatologist comments: 'To not require steroids would be very good, and that was the purpose of the avacopan trial.'
Physicians are eager for steroid-sparing treatments, which explains the positive feedback about avacopan’s ability to get patients off steroids in as quickly as a month.
An analyst from the research firm, stated: 'To supplant current therapies, newer agents must be able to induce long-term remission, reduce corticosteroid burden, and prevent relapses.'
Few companies are developing therapies for AAV to induce remission on minimal steroids; the main primary outcome across AAV trials, including:
- AstraZeneca’s benralizumab for eosinophilic GPA (EGPA)
- GlaxoSmithKline’s depemokimab for EGPA
Table of Contents
1. DISEASE OVERVIEW- A heterogenous group of chronic, life-threatening, autoimmune disorders marked by inflammation of small-to-medium blood vessels
- Figure 1.1. ANCA-associated vasculitis autoantibodies
- Blocking neutrophil priming has a therapeutic role in AAV management
- Figure 1.2. Pathogenesis of AAV and associated drug targets
- Disease definition
- Figure 2.1. Diagnosed prevalent cases of ANCA-associated vasculitis by region
- Table 2.1. Diagnosed prevalent and drug-treated patients in the US and EU5
- Overview
- Figure 3.1. Referral and diagnostic pathway for AAV patients
- Steroid-free long-term disease remission is a difficult-to-achieve goal in AAV
- Table 3.1. Treatment goals for AAV patients
- Figure 3.2. Physician-reported percentage of ANCA-vasculitis patients receiving some form of drug therapy
- Treatment flow for ANCA-associated vasculitis (AAV)
- Immune suppression is the mainstay of care in both induction and maintenance phases
- Figure 3.3. Physician-reported current treatment share for AAV patients
- Figure 3.4. Physician-reported % of patients with refractory disease
- Upsides and downsides of current AAV treatments
- Relapse rates are high in AAV; over 15% of AAV patients do not achieve remission with current txs
- Figure 3.5. Physician-reported proportion of AAV pts achieving different levels of disease responses
- Table 3.2. Physician-reported remission and relapse patterns in AAV patients
- Avacopan is viewed favorably by physicians for its oral dosing an quick steroid-tapering ability
- Figure 3.6. Physician-reported experience with/impression of new AAV therapies
- Physician perspectives on avacopan product attributes
- Key treatment dynamics that will shape disease management and drug use in AAV
- Table 3.3. Must-know AAV treatment dynamics
- Improvements over steroid-sparing ability and/or steroid-free remission is the future of AAV therapy
- Figure 3.7. Improvement dynamics of AAV market evolution
- Overview
- Figure 4.1. Top unmet needs in ANCA-associated vasculitis
- Figure 4.2. Physician-reported unmet needs in ANCA-associated vasculitis
- Physician perspectives on unmet needs in AAV
- Overview
- Figure 5.1. Physician-reported perspectives on promising targets/mechanisms of action for AAV
- Table 5.1. Comparison of targets within the terminal complement pathway
- The pipeline for AAV is sparse with three therapies targeting the immune system
- Table 5.2. Comparison of ongoing trials of therapies for ANCA-associated vasculitis
- Physician perspectives on drug development in AAV
- Overview
- Table 6.1. Current AAV therapy pricing, U.S.
- Table 6.2. Typical U.S. commercial payer coverage of approved AAV therapies
- The recenty acquired Chemocentryx and GSK have laid a pathway to increase access
- Table 6.3. The 3 P’s of measuring access for new therapies entering the AAV market based on Tavneos
- Primary market research approach
- Epidemiology methodology
Samples
LOADING...
Companies Mentioned
- Amgen
- GlaxoSmithKline
- ChemoCentryx / Amgen
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- AstraZeneca
